AIM
LKFT

Acrospire Investment Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Acrospire Investment Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-7
Closed -$1K – 582
2017
Q2 		$1K Hold
7
– – ﹤0.01% 2091
2017
Q1 		$1K Buy
+7
New +$504 ﹤0.01% 2146
2016
Q4 		– Sell
-700
Closed -$45K – 2288
2016
Q3 		$45K Buy
+700
New +$39.4K 0.03% 1129

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acrospire Investment Management's LKFT Position: Q3 2017 in Review

Acrospire Investment Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q3 2017, closing a stake of 7 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in LKFT in Q3 2016 and held it in 3 quarters. The position peaked at $45K in Q3 2016. 69 funds tracked by Wall St. Rank hold LKFT as of Q3 2017.

  • Acrospire Investment Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 7 Lakefront Biotherapeutics American Depositary Shares shares in Q3 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $45K in Q3 2016.
  • 69 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.